VANCOUVER, British Columbia, June 08, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the IND-enabling studies BetterLife’s 2-bromo-LSD (“BETR-001”) continue to progress.

Source

Previous articleAre You Attending PS2023? Here’s Where to Find Psychedelics Today in Denver
Next articleMIND CURE AND LNG ENERGY GROUP PROVIDE UPDATE ON PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION